文献速递妇科生殖医学

1990至2019年204个国家和地区多囊卵巢综合征的患病率、发病率及伤残损失健康生命年

Prevalence, incidence and years lived with disability due to polycystic ovary syndrome in 204 countries and territories, 1990-2019.
PubMed 文献 · Hum Reprod · 2022-01-01

该研究基于2019年全球疾病负担研究数据,系统分析1990至2019年204个国家和地区多囊卵巢综合征的患病率、发病率和伤残损失健康生命年。2019年全球年龄标化点患病率为每10万1677.8,年发病率为每10万59.8,伤残损失健康生命年率为每10万14.7,较1990年分别增加30.4%、29.5%和29.9%。

要点

  • 2019年全球年龄标化点患病率为每10万1677.8,年发病率为每10万59.8。
  • 2019年全球年龄标化伤残损失健康生命年率为每10万14.7,较1990年增加29.9%。
  • 全球患病病例数和点患病率分别在25-29岁和40-44岁年龄组达到峰值。

核心结论

  • 全球多囊卵巢综合征负担以惊人速度增加,已成为主要公共卫生问题。
  • 提高公众对该常见病的认识、改善管理方案和增加支持以减少导致进一步并发症的因素,需成为公共卫生优先事项。

研究设计与样本

  • 对204个国家和地区多囊卵巢综合征患病率、发病率和伤残损失健康生命年进行系统分析。
  • 数据取自2019年全球疾病负担研究中1990至2019年204个国家和地区的点患病率、年发病率和伤残损失健康生命年。
  • 呈现计数和年龄标化率(每10万)及其相应的95%不确定性区间。

主要发现

  • 2019年全球年龄标化点患病率为每10万1677.8(95% UI:1166.0至2192.4),较1990年增加30.4%。
  • 2019年全球年龄标化年发病率为每10万59.8(95% UI:41.7至78.9),较1990年增加29.5%。
  • 2019年全球年龄标化伤残损失健康生命年率为每10万14.7(6.3至29.5),较1990年增加29.9%。
  • 2019年年龄标化点患病率估计最高的国家为意大利(7897.0)、日本(6298.7)和新西兰(5419.1)。
  • 全球患病病例数在25-29岁年龄组达到峰值,点患病率在40-44岁年龄组达到峰值,且在区域和国家水平上多囊卵巢综合征负担与 socio-demographic index 呈正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 多囊卵巢综合征定义方式的差异是主要局限性,妨碍了不同地区间的有效比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the global, regional and national burden of polycystic ovary syndrome (PCOS), by age and socio-demographic index (SDI), over the period 1990-2019? SUMMARY ANSWER: In 2019, the global age-standardized point prevalence, incidence and years lived with disability (YLD) of PCOS were 30.4, 29.5 and 29.9 per 100 000 population, respectively. WHAT IS KNOWN ALREADY: Data from the Global Burden of Disease (GBD) study 2017 showed that the global age-standardized PCOS incidence rate increased 1.45% over the period 1990-2017. STUDY DESIGN, SIZE, DURATION: A systematic analysis of the PCOS prevalence, incidence and YLDs across 204 countries and territories was performed. PARTICIPANTS/MATERIALS, SETTING, METHODS: Data on the point prevalence, annual incidence and YLDs due to PCOS were retrieved from the GBD study 2019 for 204 countries and territories from 1990 to 2019. The counts and age-standardized rates (per 100 000) are presented, along with their corresponding 95% uncertainty intervals (UIs). MAIN RESULTS AND THE ROLE OF CHANCE: In 2019, the global age-standardized point prevalence and annual incidence rates for PCOS were 1677.8 (95% UI: 1166.0 to 2192.4) and 59.8 (95% UI: 41.7 to 78.9) per 100 000, which represents a 30.4% and 29.5% increase since 1990, respectively. Moreover, the global age-standardized YLD rate in 2019 was 14.7 (6.3-29.5), an increase of 29.9% since 1990. In 2019, Italy (7897.0), Japan (6298.7) and New Zealand (5419.1) had the highest estimated age-standardized point prevalences of PCOS. Globally, the number of prevalent cases and the point prevalence of PCOS peaked in the 25-29 years and 40-44 years age groups, respectively. Positive associations were found between the burden of PCOS and the SDI at the regional and national levels. LIMITATIONS, REASONS FOR CAUTION: Variations in how PCOS was defined is a major limitation that prevents valid comparisons between different regions. WIDER IMPLICATIONS OF THE FINDINGS: Globally, the burden of PCOS has increased at an alarming rate, making it a major public health concern. Increasing public awareness about this common condition, improving management options and increasing support to reduce factors which lead to further complications, need to be public health priorities. STUDY FUNDING/COMPETING INTEREST(S): The Bill and Melinda Gates Foundation, who were not involved in any way in the preparation of this manuscript, funded the GBD study. The Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant No. 28709) also supported the present report. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Safiri S, Noori M, Nejadghaderi SA, et al. Prevalence, incidence and years lived with disability due to polycystic ovary syndrome in 204 countries and territories, 1990-2019. Hum Reprod. 2022. PMID: 35586937. doi:10.1093/humrep/deac091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。